COVID-19: How is Severity of the Disease Related to Antibody Response?
Researchers from the Paul-Ehrlich-Institut jointly with teams of the University Hospital at Frankfurt/Main and the Leibniz Institute for Primate Research (Leibniz-Instituts für Primatenforschung) at Göttingen have studied the antibody response of Covid-19 patients in Germany. The aim was to gain new insights into the course of the disease and immune reactions, and to identify possible protection correlates required for the development of vaccines and therapeutic antibodies. The Journal of Infectious Diseases reports on the results of the study in its online version of 31 October 2020.
Coronavirus SARS-CoV-2 attacked by antibodies
Kateryna Kon/Shutterstock.com
More than 47 million people have so far become infected with coronavirus SARS-CoV-2 worldwide, and around 1.2 million deaths are related to a SARS-CoV-2 infection. Courses of infection with SARS-CoV-2 differ greatly between infected persons. While part of those infected do not develop many signs of disease at all, others have a serious outcome in which different organs can be affected. In slightly less than two percent of the cases confirmed in Germany, the disease takes a lethal course. Developing effective therapeutic approaches requires extensive insights into the pathogenesis of SARS-CoV-2 and the immunological processes involved. These insights are also designed to understand why courses of disease differ greatly between individuals. Besides the processes of innate immune response, above all two pillars of acquired immunity are key to the immune response of coronavirus. SARS-CoV-2: On the one hand, there is the formation of specific antibodies (immunoglobulins), which can neutralise and inactivate the virus. This immune response is called humoral immune response. The other pillar refers to the formation of specific immune cells (T-cells), the cellular immune response, which can kill infected cells.
Professor Barbara Schnierle, head of Section "AIDS, New and Novel Pathogens", and her teams, and Dr Heinrich Scheiblauer, deputy head of the Testing Laboratory for In-vitro Diagnostic Medical Devices jointly with researchers of the University Hospital at Frankfurt/Main and the Leibniz-Institut for Primate Research at Göttingen, characterised the humoral immune response – the antibody formation – in a cohort of 143 COVID-19 patients at the University Hospital at Frankfurt/Main. They identified SARS-CoV-2-specific antibodies by means of enzyme-linked immunosorbent assay (ELISA). The neutralisation activity, i.e. the ability of the antibody to neutralise the attachment of the SARS-CoV-2 virus to the cellular ACE2 receptors and thus the infection of new cells was analysed using so-called pseudo-typed lentiviral vectors. These are replication competent virus particles equipped with the spike protein of the SARS-CoV-2 virus, which can bind to ACE2 receptors.
Around three quarters of the 143 COVID-19 patients had a minor outcome of the disease. In older patients, however, especially male patients, serious cases were more common. The clinical degree of severity showed a positive correlation with the titre of SARS-CoV-2 neutralising antibodies in the serum samples of the patients. Besides, titres of particular antibodies, immunoglobulins (Ig) IgG and IgA targeted against the SARS-CoV-2 spike protein or the receptor binding domain (RBD) in the spike protein correlated with the severity of the disease. In patients with a clinically less serious course, a decrease in IgG antibody titres was detected in blood samples collected later.
Altogether, the neutralising antibody titres of patients with a mild course of disease were very low. Higher titres were only identified in persons with a serious outcome. This confirms previously reported observations, which showed that most convalescent plasma samples from persons who had recovered from COVID-19, do not reveal high neutralising antibody activity. The possibility of cross-reactivity has frequently been discussed: This means that previous exposure to related harmless human coronaviruses may equip the immune system with better protection from a SARS-CoV-2.
The human coronavirus NL63 (HCoV-NL63) was first described in 2004. It causes minor to medium severe infections of the airways. Serological data on NL63 infections are available mainly from children and point to a possible high frequency of HCoV-NL63 infection during childhood. This gives rise to speculations that existing immunity against HCoV-NL63 or other common cold coronaviruses may lower the risk of a serious course of disease. The study referenced here showed some evidence of a correlation between a serious course of COVID-19 disease and a low HcoV-NL63-neutralising activity, however, only a small data volume concerning this is available, but the evidence gained here will certainly justify conducting further studies.
Original publication
Henss L, Scholz T, von Rhein C, Wieters I, Borgans F, Eberhardt FJ, Zacharowski K, Ciesek S, Rohde G, Vehreschild M, Stephan C, Wolf T, Hofmann-Winkler H, Scheiblauer H, Schnierle BS (2020); "Analysis of humoral immune responses in SARS-CoV-2 infected patients"; J Infect Dis Oct 31 [Epub ahead of print].
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
